One-Year Open-Label Study of Entacapone in Patients with Advanced Parkinson Disease

BACKGROUND AND PURPOSE: A carboxy-O-methyl transferase inhibitor entacapone has been introduced as an adjuvant drug for Parkinson disease (PD) patients. Although clinical trials reported beneficial role of entacapone, a long-term trial over 3 years failed to show significant effect. The goals of thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Tae-Beom, Im, Joo-Hyuk, Lee, Myoung Chong, Kim, Jae Woo, Lee, Won Yong, Jeon, Beom S.
Formato: Texto
Lenguaje:English
Publicado: Korean Neurological Association 2007
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686863/
https://www.ncbi.nlm.nih.gov/pubmed/19513296
http://dx.doi.org/10.3988/jcn.2007.3.2.82

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686863/
https://www.ncbi.nlm.nih.gov/pubmed/19513296
http://dx.doi.org/10.3988/jcn.2007.3.2.82

Ejemplares similares